Corpus ID: 40756821

Folic acid alters methotrexate availability in patients with rheumatoid arthritis.

@article{Bressolle2000FolicAA,
  title={Folic acid alters methotrexate availability in patients with rheumatoid arthritis.},
  author={F Bressolle and Jean Marie Kinowski and Jacques Morel and B Pouly and Jacques Sany and Bernard Combe},
  journal={The Journal of rheumatology},
  year={2000},
  volume={27 9},
  pages={
          2110-4
        }
}
OBJECTIVE To evaluate the effects of repeated doses of folic acid on the pharmacokinetics of methotrexate (MTX) in patients with rheumatoid arthritis. METHODS We studied 20 patients (ages 30-78 years) who received MTX intramuscularly (10 mm/week). MTX was administered alone or after treatment with folic acid (5 mg tablet once daily) for 13 days. Plasma samples were collected 2 and 8 h after dose intake. MTX concentrations in plasma and ultrafiltrate samples were measured by fluorescence… Expand
Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis
Abstract This article evaluates the relationship between the pharmacokinetics of methotrexate (MTX), its efficacy in the treatment of rheumatoid arthritis (RA), and serum folic acid (FA) levels. TheExpand
Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis
This article evaluates the relationship between the pharmacokinetics of methotrexate (MTX), its efficacy in the treatment of rheumatoid arthritis (RA), and serum folic acid (FA) levels. TheExpand
Usefulness of daily folic acid supplementation during methotrexate treatment of Japanese patients with rheumatoid arthritis
Abstract Objectives We investigated the effect of daily folic acid supplementation on methotrexate (MTX) toxicity and efficacy in Japanese patients with rheumatoid arthritis (RA). Methods We followedExpand
The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis
TLDR
The antipsoriatic effect of MTX during the remission-induction phase of treatment is influenced by folate status and may be significantly less if combined treatment with FA is used, irrespective of pre-treatment folate levels. Expand
What dose of folic acid to use with methotrexate in rheumatoid arthritis?
TLDR
It is likely that some of the adverse effects of methotrexate are due to folate antagonism, and the main factor affecting adherence to metotrexate is the occurrence of adverse effects, rather than lack of response. Expand
Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines.
TLDR
An individually adjusted supply of folic acid rather than folinic acid is proposed for supplementation during methotrexate therapy of patients with rheumatoid arthritis, addressing both the timing of folate supplementation and the weekly folate-to-methotrexate ratio. Expand
The Effect of Folate Supplementation on Methotrexate Efficacy and Toxicity in Psoriasis Patients and Folic Acid Use by Dermatologists in the USA
TLDR
Dermatologists were the least likely specialists to supplement MTX with folic acid, and there is a scarcity of literature describing the effect of folate on MTX toxicity and efficacy in psoriasis patients. Expand
Folate supplementation during methotrexate therapy for rheumatoid arthritis.
TLDR
Clinical trials related to folate supplementation during MTX therapy for RA are reviewed, finding that FA supplementation has a beneficial effect on homocysteine (hcy) metabolism and may prevent the formation of the less effective metabolite 7-hydroxy-MTX. Expand
The use of methotrexate in rheumatoid arthritis.
TLDR
MTX is an effective DMARD with a relatively safe profile compared with other therapies and it is essential that patients be monitored carefully to reduce the potential serious toxicities of MTX. Expand
Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis
TLDR
Several lines of evidence clearly suggest that MTX does not act simply as a cytotoxic (antiproliferative) agent for the cells responsible for the joint inflammation in RA. Expand
...
1
2
3
...